Arcturus Therapeutics Holdings Inc. Stock
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.32 USD | -4.78% | -19.11% | -16.52% |
Financials (USD)
Sales 2024 * | 147M | Sales 2025 * | 241M | Capitalization | 708M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | 2M | EV / Sales 2024 * | 2.34 x |
Net cash position 2024 * | 364M | Net cash position 2025 * | - | EV / Sales 2025 * | 2.94 x |
P/E ratio 2024 * |
-10.1
x | P/E ratio 2025 * |
-105
x | Employees | 180 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Arcturus Therapeutics Holdings Inc.
1 day | -4.78% | ||
1 week | -19.11% | ||
Current month | -22.06% | ||
1 month | -20.56% | ||
3 months | -18.44% | ||
6 months | +23.05% | ||
Current year | -16.52% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 13-02-28 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 19-08-31 |
Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 19-08-31 |
James F. Barlow
BRD | Director/Board Member | 65 | 18-05-26 |
Peter Farrell
CHM | Chairman | 81 | 18-05-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 26.32 | -4.78% | 607,514 |
24-04-17 | 27.64 | -8.26% | 621,074 |
24-04-16 | 30.13 | +2.80% | 385,057 |
24-04-15 | 29.31 | -3.68% | 609,596 |
24-04-12 | 30.43 | -6.48% | 405,050 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.52% | 708M | |
-1.82% | 41.35B | |
+41.93% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- ARCT Stock